Syncona Announced Earlier, Quell Signed Collaboration Agreement With AstraZeneca
Portfolio Pulse from Charles Gross
Quell Therapeutics has signed a collaboration agreement with AstraZeneca to develop, manufacture, and commercialize engineered T-regulatory cell therapies for type 1 diabetes and inflammatory bowel disease. Quell will receive $85 million upfront and potential payments of over $2 billion contingent on milestones, plus tiered royalties.
June 09, 2023 | 8:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca partners with Quell Therapeutics to develop cell therapies for autoimmune diseases, investing $85 million upfront with potential milestone payments of over $2 billion.
The collaboration with Quell Therapeutics expands AstraZeneca's portfolio in autoimmune disease treatments. The $85 million upfront investment and potential milestone payments of over $2 billion indicate a strong commitment to the partnership and could lead to significant revenue generation if the therapies are successful.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100